Application Serial No.: 10/644,038

Attorney Docket No.: 03495.0194-01

Express Mail Label No.: EV 799294695 US

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-9 (Canceled).

- 10. (Currently Amended) A purified polypeptide encoded by a nucleic acid molecule selected from the group-comprising consisting of:
 - (A) a purified nucleic acid molecule of sequence SEQ ID NO: 2;
- (B) a purified nucleic acid molecule encoding the amino acid sequence SEQ ID NO: 1; and
- (C) a purified nucleic acid molecule degenerate from SEQ ID NO: 2 as a result of the genetic code; or
- (D)—a purified nucleic acid molecule that encodes a core+1 polypeptide or a variant of core+1 polypeptide, wherein the variant is detectable by Western analysis using HCV-positive human serum or monoclonal antibody against core protein, and wherein the amino-acid sequence of the variant shares at least 80% identity with a native core+1 polypeptide amino-acid sequence.
- 11. (Original) A purified polypeptide according to claim 10 having a molecular weight of approximately 17.5 kD as determined by SDS-PAGE.
- 12. (Original) A purified polypeptide according to claim 10 in non-glycosylated form.
 - 13-16. (Cancelled)
 - 17. (Original) Purified antibodies that bind to a polypeptide of claim 10.

Application Serial No.: 10/644,038 Attorney Docket No.: 03495.0194-01 Express Mail Label No.: EV 799294695 US

18. (Original) Purified antibodies according to claim 17, wherein the antibodies are monoclonal antibodies.

Claims 19-32. (Cancelled)

33. (Original) An immunological complex comprising a core+1 polypeptide of HCV and an antibody that specifically recognizes said polypeptide.

Claims 34-44. (Cancelled)